123 related articles for article (PubMed ID: 10327033)
1. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.
Groener MG; van Ineveld BM; Byttebier G; van Hout BA; Rutten FF
Anticancer Drugs; 1999 Mar; 10(3):283-8. PubMed ID: 10327033
[TBL] [Abstract][Full Text] [Related]
2. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
Sculpher M; Palmer MK; Heyes A
Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
[TBL] [Abstract][Full Text] [Related]
3. Mature results from three large controlled studies with raltitrexed ('Tomudex').
Cunningham D
Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
[TBL] [Abstract][Full Text] [Related]
4. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
[TBL] [Abstract][Full Text] [Related]
5. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
Cunningham D; Zalcberg JR; Rath U; Olver I; Van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
Eur J Cancer; 1995 Nov; 31A(12):1945-54. PubMed ID: 8562146
[TBL] [Abstract][Full Text] [Related]
6. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
Ross P; Heron J; Cunningham D
Eur J Cancer; 1996; 32A Suppl 5():S13-7. PubMed ID: 8958037
[TBL] [Abstract][Full Text] [Related]
7. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Gunasekara NS; Faulds D
Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
[TBL] [Abstract][Full Text] [Related]
8. [Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review].
Selke B; Lebrun T; Comte S
Bull Cancer; 2003 Feb; 90(2):143-9. PubMed ID: 12660133
[TBL] [Abstract][Full Text] [Related]
9. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
Jansman FG; Postma MJ; van Hartskamp D; Willemse PH; Brouwers JR
Clin Ther; 2004 Apr; 26(4):579-89. PubMed ID: 15189755
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer.
Kerr DJ
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S11-5. PubMed ID: 9376632
[TBL] [Abstract][Full Text] [Related]
11. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
[TBL] [Abstract][Full Text] [Related]
12. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer.
Zalcberg J
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S17-22. PubMed ID: 9376633
[TBL] [Abstract][Full Text] [Related]
13. Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics.
Norum J; Balteskard L; Edna TH; Laino R; Wählby L; Rønning G
J Chemother; 2002 Jun; 14(3):301-8. PubMed ID: 12120887
[TBL] [Abstract][Full Text] [Related]
14. Raltitrexed-based chemotherapy for advanced colorectal cancer.
Liu Y; Wu W; Hong W; Sun X; Wu J; Huang Q
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):219-25. PubMed ID: 24388340
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M;
Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670
[TBL] [Abstract][Full Text] [Related]
16. Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer.
Aristides M; Chen J; Schulz M; Williamson E; Clarke S; Grant K
Pharmacoeconomics; 2002; 20(11):775-84. PubMed ID: 12201796
[TBL] [Abstract][Full Text] [Related]
17. The costs of managing advanced colorectal cancer: a broad perspective.
Kerr DJ; O'Connor KM
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S23-6. PubMed ID: 9376634
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].
Locher C; Auperin A; Boige V; Alzieu L; Pignon JP; Abbas M; Ducreux M
Gastroenterol Clin Biol; 2001; 25(8-9):749-54. PubMed ID: 11598535
[TBL] [Abstract][Full Text] [Related]
19. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
Cunningham D; Zalcberg JR; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748
[No Abstract] [Full Text] [Related]
20. Raltitrexed in colorectal cancer.
Drug Ther Bull; 1996 Oct; 34(10):78-80. PubMed ID: 8936802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]